Latest News in the pharma Industry
All
Collaboration to develop innovative technologies
20 Dec 2017
Project will innovate technologies in epigenetic characterisation for patient stratification in renowned precision medicine.
Read more
NIH study uncovers clues about why common cancer drug causes hearing loss
20 Dec 2017
Researchers find target to protect hearing during chemotherapy treatment.
Read more
Impax sells Taiwan manufacturing facility
20 Dec 2017
Bora Pharmaceuticals to pay purchase price of $18.5 million and will have the rights to market and sell Impax's branded Parkinson's drug Rytary (Numient outside the US) in Taiwan.
Read more
Major changes for bio supply forecast in 2018 by bioLIVE
19 Dec 2017
Integration of supply chain a critical issue as industry globalises, with a resurgence in European manufacturing and biotech markets forecast.
Read more
Hikma signs licensing agreement with Celltrion for third biosimilar product in MENA region
19 Dec 2017
Truxima is mAb biosimilar to Roche's MabThera (rituximab).
Read more
Regeneron and ISA Pharma to advance immuno-oncology treatment
18 Dec 2017
Collaboration to conduct clinical trials of the combination treatment in both cervical and head-and-neck cancer.
Read more
Teva to axe 25% of its total workforce
18 Dec 2017
Total cost base to be reduced by $3 billion by the end of 2019.
Read more
Femarelle launches new women’s supplement line in US
18 Dec 2017
Targeted formulas support symptoms before, during and after menopause.
Read more
Lilly and Rimidi to make diabetes management easier
15 Dec 2017
Companies will strive to make diabetes management easier through effective use of connected devices and a diabetes management software platform.
Read more
Major breakthrough for new haemophilia A treatment
15 Dec 2017
Drug trials provide mind-blowing results.
Read more
New formulation of Oncaspar receives Marketing Authorization in Europe for patients with ALL
14 Dec 2017
Freeze-dried, or lyophilized, formulation aims to improve supply management by providing the same dosing regimen as liquid Oncaspar but with a three-times longer shelf life of up to 24 months.
Read more
CMC Biologics and Harpoon Therapeutics collaborate on exciting new TriTAC molecules
14 Dec 2017
First clinical candidate, HPN424, is in development for the treatment of metastatic prostate cancer and expected to enter Phase I clinical trials in 2018.
Read more